Podcasts about European Heart Journal

I'm joined by Dr. Jeffrey Sankoff to talk about three exercise “rules” you may be allowed to break: you don't always need to spread workouts across the week, intensity doesn't have to come from a formal interval session, and most short workouts don't require a complicated hydration or fueling plan.The Exercise Rules You're Allowed to BreakHave you ever skipped a workout because you couldn't do the “right” one? Maybe you didn't have time for the gym, a long hike, or a structured bike ride. Today, we revisit Voltaire's reminder that “the great is the enemy of the good” and apply it to exercise. The evidence is reassuring: weekend workouts count, short bursts of effort during the day count, and for most workouts under an hour, hydration hype may matter far less than we've been led to believe.Dr. Jeffrey Sankoff, an ER physician, Ironman triathlete, triathlon coach, and host of the evidence-focused TriDoc Podcast, joins me for this conversation. While Jeff works with endurance athletes, today's discussion is for anyone who wants to live long and well while still managing the realities of work, family, travel, and everyday life.First, we break the calendar rule. Many people assume exercise has to be spread evenly throughout the week, but a 2024 Circulation study on “weekend warrior” physical activity found that people who concentrated their moderate-to-vigorous exercise into one or two days still had lower risk for many diseases compared with inactive people, especially cardiometabolic conditions such as hypertension, diabetes, obesity, and sleep apnea. The study was observational, so it does not prove weekend-only exercise is ideal, and injury risk still matters. But the practical message is clear: if weekdays are impossible, weekends still count. Next, we break the formal-interval rule. High intensity does not always have to mean a structured HIIT class, a bike trainer, or a carefully timed workout. A 2026 European Heart Journal study found that a higher percentage of vigorous physical activity was associated with lower risk across several chronic diseases and mortality outcomes. Even a small proportion of vigorous activity may matter, meaning short real-life bursts—taking the stairs quickly, walking briskly uphill, carrying groceries with purpose, or chasing a child or grandchild—can become meaningful movement when they raise your breathing and effort level. This study was also observational, so it cannot prove cause and effect, and anyone with medical concerns should check with their clinician before adding vigorous bursts. Finally, we break the bottle rule. For endurance races, long workouts, or hot-weather exercise, hydration, electrolytes, and carbohydrates can matter. But for many 30- to 60-minute workouts in ordinary conditions, a formal hydration or fueling plan may not be necessary. The American College of Sports Medicine's position stand emphasizes fluid replacement to support hydration during physical activity, but the need depends on duration, sweat loss, heat, and intensity. A practical “N of 1” approach is to weigh yourself before and after a typical workout to see how much fluid you actually lose. We also discuss electrolytes and carbohydrates. Electrolytes are mostly salts, and they become more relevant with long, hot, sweaty, or repeated sessions. Carbohydrate-containing drinks can help with longer endurance performance, but for a 35-minute walk or a short gym session, sugar in your bottle is usually not the bottleneck. A systematic review on carbohydrates and exercise performance found benefits in longer exercise contexts, but that does not mean every short workout needs sports drinks or gels. TakeawaysDon't let the perfect workout plan keep you from the good-enough workout you can actually do.If weekdays are packed, a weekend warrior approach may still provide meaningful health benefits.Look for small bursts of vigorous effort in daily life, and for most workouts under an hour, water when thirsty is usually enough.Send us Fan MailSupport the show

+++ Oktopus-Fang hat sich um 7700% gesteigert +++ Mehr Zivilist*innen sterben durch Drohnen +++ Mammografiebilder helfen bei Herzgesundheit +++ Super-Erdbeben in L. A. wird wahrscheinlicher +++**********Weiterführende Quellen zu dieser Folge:Bericht zu Oktopussen vor Großbritannien im Umwelt-Magazin ECO: "UK Study Examines Impacts of Rising Octopus Numbers on Coasts and Communities", 08.06.2026Explosivwaffen-Monitor 2025 bei Handicap International, 10.06.2026Studie über Mammografie und Herzerkrankungen im European Heart Journal: "Artificial intelligence–based quantification of breast arterial calcifications to predict cardiovascular morbidity and mortality", Mai-Ausgabe 2026Studie zur Erbebengefahr in Kalifornien im Fachmagazin JGR Solid Earth: "Cajon Pass and the Southern San Andreas Fault System: Earthquake Cycle Stress Accumulation and Present-Day Loading", 03.06.2026**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

With Johann Bauersachs, Hannover Medical School, Hannover - Germany and Samira Soltani, Hannover Medical School, Hannover - Germany. Link to European Heart Journal paper Link to European Heart Journal editorial

That scary nutrition headline about preservatives and high blood pressure is everywhere right now and it's easy to jump straight from “linked” to “proven.” We slow it down and do what we'd do in an exam room: look at what the study actually says, what it doesn't say, and how to translate it into real-life choices that protect your heart without turning grocery shopping into a panic spiral.We talk through a new European Heart Journal paper using data from the NutriNet-Santé cohort (over 112,000 adults followed for nearly eight years) that finds several common food preservatives are associated with a higher risk of developing hypertension and cardiovascular disease. We explain why that word “associated” matters, how observational nutrition research can be confounded by overall ultra-processed food intake, sodium, fiber, lifestyle, and other factors, and why the results are best viewed as a signal not a verdict.Then we get practical by walking through a typical kitchen day and pointing out where you might run into additives like sodium nitrite, potassium sorbate, phosphoric acid, citric acid, and calcium propionate: breads, deli meats, chips, frozen meals, and even cola beverages. We also share the habits with the strongest evidence for blood pressure control: more minimally processed foods, more fruits and vegetables, less excess sodium, regular activity, better sleep, and stress management.If you found this helpful, subscribe, share it with a friend or neighbor, and leave a review so more people can find clear, patient-centered health info. What's the first preservative you spot when you check five labels in your kitchen?Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

With Philipp Sommer, Heart and Diabetes Center NRW, Bad Oeynhausen - Germany and Vanessa Sciacca, Heart and Diabetes Center NRW, Bad Oeynhausen - Germany. Link to European Heart Journal paper Link to European Heart Journal editorial

CardioNerds Dr. Joseph Kassab, Dr. Mariana Garcia-Arango, and Dr. Christopher Mason explore the technological revolution of Coronary CT Angiography (CCTA) with expert faculty Dr. Michael Gallagher. The discussion details how CCTA has evolved into a frontline diagnostic and preventive tool, moving beyond simple anatomy to incorporate physiology via CT-FFR and biology through AI-driven plaque quantification. The episode reviews landmark evidence like the SCOT-HEART and PROMISE trials, the nuances of CAD-RADS 2.0 reporting, and the emerging role of AI in monitoring treatment response and personalizing cardiovascular care. Critically, they also discuss some of the assumptions and limitations of these techniques. Stay tuned for a matching review article to be submitted to US Cardiology Review, the official Journal of CardioNerds. This episode was supported by an independent medical education grant from HeartFlow. All CardioNerds education is planned, produced, and reviewed solely by CardioNerds.  Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here. CardioNerds Multimodality Cardiovascular Imaging PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll Pearls Shift in Paradigm: CCTA is no longer just an anatomic test; with some key limitations, it can provide anatomy, physiology (CT-FFR), and plaque biology (AI-CPA) in a single non-invasive scan. The “Power of Zero” vs. Plaque: While a normal CCTA has a >95% negative predictive value, future MIs often arise from non-obstructive plaque that traditional stress tests might miss. CAD-RADS 2.0 Utility: The addition of plaque burden modifiers (P1–P4) is a “game changer,” allowing clinicians to identify high-risk patients who need aggressive lipid-lowering despite having only mild stenosis. CT-FFR as a Virtual Stress Test: CT-FFR uses computational fluid dynamics to simulate blood flow, potentially reducing unnecessary invasive catheterizations by approximately 61% without sacrificing safety. Seeing the Invisible: AI-based quantitative plaque analysis (QCPA) can identify “subvisual” plaque and low-attenuation (lipid-rich) components that are the primary drivers of acute coronary syndromes. Show Notes How has the role of CCTA changed compared to traditional functional testing? Historically, stress testing answered “is there ischemia today?”, which often reflects late-stage disease. CCTA identifies disease across the entire spectrum, asking “is there atherosclerosis and how much plaque is present?”. Landmark evidence: SCOT-HEART showed a 41% relative risk reduction in MI at 5 years attributed to intensified preventive therapies, and PROMISE showed CCTA was better at selecting patients who truly needed invasive angiography. Diagnostic CCTA imaging depends on the protocol, contrast timing, heart rate, heart rhythm, breathholding, scanner quality, and several patient factors (obesity, prior stents, heavy calcification, complex bypass anatomy, and motion artifact all may limit imaging). “CCTA is exceptional for the right patient, with the right scanner, and the right team.” What are the key modifiers introduced in CAD-RADS 2.0, and why do they matter? CAD-RADS 2.0 moved beyond stenosis severity to include plaque burden (P0 to P4), high-risk plaque (HRP) features, and the presence of ischemia based on CT-FFR. It serves as a clinical decision support tool: a patient with mild (25-49%) stenosis but “extensive” (P4) plaque burden is considered high risk and warrants aggressive risk factor modification. How is CT-FFR calculated, and when is it most useful in clinical practice? CT-FFR uses resting CCTA data and computational fluid dynamics to create a 3D model of coronary flow during simulated maximal hyperemia. It is often used for intermediate lesions (40–90% stenosis) to predict if they are  ischemia-producing, guiding the decision whether to proceed with invasive angiography.  The assumptions necessary for this computational modeling may not apply well to patients with microvascular dysfunction, significant myocardial scar or prior infarction, or ventricular hypertrophy. Still, data indicate that CT-FFR performs similarly to PET in predicting hemodynamically significant lesions.  CT-FFR performs well at the extremes (either clearly normal or clearly abnormal). Accuracy dips, however, in the intermediate range (~0.75-0.80), where decision-making is most critical. In this grey zone, additional factors can help guide the approach, including the amount of myocardium supplied, translesional gradient, and plaque features.   CT-FFR has not been validated in distal segments, stented segments, heavily calcified coronary arteries, or in patients with severe aortic stenosis. Caution with CT-FFR should be utilized in very calcified coronary segments.  What is AI-based quantitative plaque analysis (QCPA), and what metrics are ready for clinical use? This is potentially a paradigm shift, moving away from stenosis-centric thinking to a more disease burden and plaque biology focus. QCPA uses deep learning algorithms to automatically segment the vessel wall and quantify plaque volume in mm³. Ready for “prime time” metrics include: Total Plaque Volume (TPV), non-calcified plaque volume, and Low-Attenuation Plaque (LAP) burden. Can serial CCTA be used to monitor the effectiveness of medical therapies like statins? While not yet a routine guideline-driven practice, trials like PARADIGM and EVAPORATE show that therapies can stabilize plaque; notably, CCTA is better for monitoring than CAC scores, which can be misleading as statins often increase plaque calcification as part of the stabilization process. There are no randomized trials that serial CCTAs improve outcomes. Cost and radiation exposure will be notable limitations. Serial scan timing, scan acquisition and interpretation standardization would be key. Dr. Gallagher notes that we are moving toward a world in which plaque burden may become a “treatment biomarker,” similar to tumor burden in oncology.  References 1. Coronary Computed Tomography Angiography From Clinical Uses to Emerging Technologies: JACC State-of-the-Art Review. Abdelrahman KM, Chen MY, Dey AK, et al. Journal of the American College of Cardiology. 2020;76(10):1226-1243. doi:10.1016/j.jacc.2020.06.076. 2. Non-Invasive Imaging in Coronary Syndromes: Recommendations of the European Association of Cardiovascular Imaging and the American Society of Echocardiography, in Collaboration With the American Society of Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Edvardsen T, Asch FM, Davidson B, et al. Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography. 2022;35(4):329-354. doi:10.1016/j.echo.2021.12.012. 3. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Gulati M, Levy PD, Mukherjee D, et al. Journal of the American College of Cardiology. 2021;78(22):e187-e285. doi:10.1016/j.jacc.2021.07.053. 4. Contemporary, Non-Invasive Imaging Diagnosis of Chronic Coronary Artery Disease. van der Bijl P, Gulati M, Saraste A, et al. Lancet (London, England). 2025;406(10519):2577-2587. doi:10.1016/S0140-6736(25)01586-7. 5. State of the Art: Evaluation and Medical Management of Nonobstructive Coronary Artery Disease in Patients With Chest Pain: A Scientific Statement From the American Heart Association. Slipczuk L, Blankstein R, Bucciarelli-Ducci C, et al. Circulation. 2025;152(23):e443-e466. doi:10.1161/CIR.0000000000001394. 6. Diagnostic Performance of Fractional Flow Reserve Derived From Coronary CT Angiography: The ACCURATE-CT Study. Li C, Hu Y, Jiang J, et al. JACC. Cardiovascular Interventions. 2024;17(17):1980-1992. doi:10.1016/j.jcin.2024.06.027. 7. Clinical Outcomes Based on Coronary Computed Tomography-Derived Fractional Flow Reserve and Plaque Characterization. Sato Y, Motoyama S, Miyajima K, et al. JACC. Cardiovascular Imaging. 2024;17(3):284-297. doi:10.1016/j.jcmg.2023.07.013. 8. Clinical Use of Coronary Computed Tomography Angiography-Derived Fractional Flow Reserve: Expert Consensus by an International Working Group. Tang CX, Leipsic JA, Nørgaard BL, et al. European Radiology. 2026;:10.1007/s00330-025-12313-6. doi:10.1007/s00330-025-12313-6. 9. Diagnostic accuracy of computed tomography–derived fractional flow reserve: a systematic review. Cook CM, Petraco R, Shun-Shin MJ, et al. JAMA Cardiol. 2017;2(7):803-810. Doi:10.1001/jamacardio.2017.1314 10. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). Nørgaard BL, Leipsic J, Gaur S, et al. J Am Coll Cardiol. 2014;63(12):1145-1155. Doi:10.1016/j.jacc.2013.11.043 11. Comparison of coronary computed tomography angiography, fractional flow reserve, and perfusion imaging for ischemia diagnosis. Driessen RS, Danad I, Stuijfzand WJ, et al. J Am Coll Cardiol. 2019;73(2):161-173. Doi:10.1016/j.jacc.2018.10.056. 12. 1-year outcomes of FFRCT-guided care in patients with suspected coronary disease: the PLATFORM study. Douglas PS, De Bruyne B, Pontone G, et al. J Am Coll Cardiol. 2016;68(5):435-445. Doi:10.1016/j.jacc.2016.05.057. 13. Comparison of an initial risk-based testing strategy vs usual testing in stable symptomatic patients with suspected coronary artery disease: the PRECISE randomized clinical trial. Douglas PS, Nanna MG, Kelsey MD, et al; PRECISE Investigators. JAMA Cardiol. 2023;8(10):904-914. Doi:10.1001/jamacardio.2023.2595. 14. Diagnostic and clinical value of FFRCT in stable chest pain patients with extensive coronary calcification: the FACC study. Mickley H, Veien KT, Gerke O, et al. JACC Cardiovasc Imaging. 2022;15(6):1046-1058. doi:10.1016/j.jcmg.2021.12.010. 15. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results From the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART). Williams MC, Kwiecinski J, Doris M, et al. Circulation. 2020;141(18):1452-1462. doi:10.1161/CIRCULATIONAHA.119.044720. 16. AI-Guided Quantitative Plaque Staging Predicts Long-Term Cardiovascular Outcomes in Patients at Risk for Atherosclerotic CVD. Nurmohamed NS, Bom MJ, Jukema RA, et al. JACC. Cardiovascular Imaging. 2024;17(3):269-280. doi:10.1016/j.jcmg.2023.05.020. 17. Interaction of AI-Enabled Quantitative Coronary Plaque Volumes on Coronary CT Angiography, FFRCT, and Clinical Outcomes: A Retrospective Analysis of the ADVANCE Registry. Dundas J, Leipsic J, Fairbairn T, et al. Circulation. Cardiovascular Imaging. 2024;17(3):e016143. doi:10.1161/CIRCIMAGING.123.016143. 18. Prognostic Value of AI-Based Quantitative Coronary CTA vs Human Reader-Based Visual Assessment: Results From the CONFIRM2 Registry. van Rosendael A, Nakanishi R, Bax JJ, et al. JACC. Cardiovascular Imaging. 2026;19(3):345-359. doi:10.1016/j.jcmg.2025.09.021.13. Pericoronary Adipose Tissue as a Marker of Cardiovascular Risk: JACC Review Topic of the Week. Tan N, Dey D, Marwick TH, Nerlekar N. Journal of the American College of Cardiology. 2023;81(9):913-923. doi:10.1016/j.jacc.2022.12.021. 19. Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy: Final Results of the EVAPORATE Trial. Budoff MJ, Bhatt DL, Kinninger A, et al. European Heart Journal. 2020;41(40):3925-3932. doi:10.1093/eurheartj/ehaa652. 20. Coronary CT Angiography Evaluation With Artificial Intelligence for Individualized Medical Treatment of Atherosclerosis: A Consensus Statement From the QCI Study Group. Schulze K, Stantien AM, Williams MC, et al. Nature Reviews. Cardiology. 2026;23(2):100-115. doi:10.1038/s41569-025-01191-6.

In this episode Dr Marilena Giannoudi discusses all things heart failure with Dr Sam McClure. They begin with how to diagnose and classify heart failure with reduced ejection fraction and heart failure with preserved ejection fraction before moving onto treatment and when to refer to the Heart Failure Team. Dr Sam McClure is a Consultant Interventional Cardiologist and Clinical Lead for Heart Failure in Sunderland. Dr Marilena Giannoudi is a cardiology registrar based in Leeds. She is Co-Chair of the Trainees and Members & Committee, a Fellow of the Higher Education Academy, and is currently undertaking a PhD. Recording Date: 30 March 2026 -- Useful Links -- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2023 Update) - https://www.escardio.org/guidelines/clinical-practice-guidelines/all-esc-practice-guidelines/focused-update-on-heart-failure-guidelines/ European Heart Journal, Volume 44, Issue 37, 1 October 2023, Pages 3627–3639 - https://academic.oup.com/eurheartj/article/44/37/3627/7246292?login=false Chronic heart failure in adults: diagnosis and management (NICE Guideline) - https://www.nice.org.uk/guidance/ng106 H2FPEF Score for Heart Failure with Preserved Ejection Fraction - https://www.mdcalc.com/calc/10105/h2fpef-score-for-heart-failure-with-preserved-ejection-fraction -- Follow us -- https://www.instagram.com/rcpedintrainees -- Upcoming RCPE events -- https://www.rcpe.ac.uk/events -- Become an RCPE Member -- https://www.rcpe.ac.uk/membership/join-college Feedback: cme@rcpe.ac.uk This podcast is from the Trainees & Members' Committee (T&MC) of the Royal College of Physicians of Edinburgh (RCPE).

In this episode, CardioNerds Dr. Colin Blumenthal, Dr. Kelly Arps, and Dr. Yong Hao Yeo are joined by electrophysiology expert Dr. Bradley Knight to discuss atrial fibrillation (AF) management in challenging clinical scenarios. We explore arrhythmias in patients with pre-excitation syndromes, particularly Wolff-Parkinson-White (WPW) syndrome, and strategies for rhythm control. We also discuss AF management in pregnancy, adult congenital heart disease, and patients with tachycardia-bradycardia (tach-brady) syndrome. This episode provides essential insights into nuanced decision-making for the care of patients with complex arrhythmia profiles. Audio editing by CardioNerds academy intern, Grace Qiu. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Atrial Fibrillation PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! PEARLS AF in WPW is a true emergency—AV nodal blocking agents can be deadly. In patients with WPW syndrome, AF can rapidly conduct through the accessory pathway, risking ventricular fibrillation and sudden death. Avoid AV nodal blockers like beta-blockers and calcium channel blockers. Catheter ablation is the first-line rhythm control strategy in WPW. Catheter ablation carries a Class I recommendation and offers >90% success. If antiarrhythmic drugs are needed, sodium channel blockers like flecainide or propafenone are preferred in patients without structural heart disease. In pregnancy, protecting the mother is protecting the fetus. An unstable mother means an unstable fetus. Rate control is the first step in AF with rapid ventricular responses and electrical cardioversion is safe when needed. Multidisciplinary care is essential. AF in congenital heart disease is often outside the pulmonary veins. Surgical scars and chamber remodeling in ACHD patients often lead to AF from non-pulmonary vein foci. Electrogram-based mapping and targeted ablation strategies are essential to increase success rate of durable rhythm control. Tachy-brady syndrome may require pacing to unlock therapy. AF may cause atrial myopathy and sinus node dysfunction. These patients often require permanent pacing to allow safe use of rate-controlling medications like beta-blockers and to prevent syncope or chronotropic incompetence. Notes: Notes drafted by Dr. Yong Hao Yeo Why is atrial tachycardia in patients with WPW syndrome dangerous? Patients with WPW commonly present with supraventricular tachycardia (SVT) due to atrioventricular reentrant circuits, either orthodromic or antidromic. This SVT can degenerate into AF. In the absence of AV nodal as the governor between the atrium and ventricles, the accessory pathway may conduct impulses rapidly and frequently. This can lead to dangerously high ventricular rates, predisposing patients to ventricular fibrillation and sudden cardiac arrest. What are some strategies for rhythm control in patients with WPW and atrial tachycardia? Catheter ablation is the first-line therapy (Class I recommendation), with a success rate of over 90%. Ablation reduces the risk of sudden cardiac arrest, though some patients may remain prone to AF. If ablation is not feasible/ contraindicated, sodium channel blockers such as flecainide and propafenone are good options in patients without ischemia or structural heart disease (Class IIa recommendation). Amiodarone should be avoided because it has a long half-life, can accumulate in the system, and may delay definitive treatment with catheter ablation. AV nodal blocking agents like beta blockers and calcium channel blockers should be avoided, as they are less effective at controlling ventricular rate in WPW and can increase conduction over the accessory pathway. These agents can also exacerbate the risk of rapid ventricular rates during AF and worsen left ventricular function. What are some special considerations in managing AF in pregnant patients? The primary goal in managing cardiovascular disease during pregnancy is to protect the mother, as fetal outcomes depend on maternal well-being. Therefore, while caution is necessary, we should avoid undertreating pregnant patients with AF. In cases of AF with rapid ventricular response (RVR), rate control is usually the first-line strategy, with beta blockers preferred over digoxin or non-dihydropyridine calcium channel blockers. It is then reasonable to initially observe for spontaneous conversion in stable patients. Antiarrhythmic drugs (AADs) are generally avoided during the first trimester, but clinical judgment on a case-by-case basis is essential. Evidence for the safety of AADs in pregnancy is limited, often derived from their use in other conditions such as fetal SVT. Flecainide and sotalol are reasonable options for rhythm control (Class IIa recommendation). Electrical cardioversion is considered safe in pregnancy and should be utilized when indicated (Do not forget!). There is no pregnancy-specific thromboembolic risk stratification tool. CHA₂DS₂-VASc scoring and the presence of risk factors like mitral stenosis can help guide anticoagulation decisions, though the magnitude of thromboembolic risk during pregnancy remains unclear. Rate control agents are typically continued during delivery due to the increased physiologic stress of labor and delivery. Multidisciplinary care is crucial and should involve obstetrics, maternal-fetal medicine, cardiology, and electrophysiology specialists. What are some key considerations for AF management in patients with adult congenital heart disease (ACHD)? Patients with repaired congenital heart disease are at increased risk for arrhythmias due to two main factors: surgical scars that create arrhythmogenic foci and mechanical remodeling of the atria or ventricles resulting from the underlying disease. In these patients with structural heart disease, sodium channel blockers may not be ideal antiarrhythmic options. When selecting an antiarrhythmic drug, clinicians must consider the nature of structural or surgical impairments, such as right bundle branch block or prolonged QT interval. It is also essential to assess renal and hepatic function (often impaired in patients with ACHD) to ensure appropriate metabolism and clearance of antiarrhythmic medications. Electrogram-based ablation strategies (those leveraging artificial intelligence are developing!) may help identify effective ablation targets, which are often outside the pulmonary veins in patients with ACHD. These individualized approaches can improve ablation success rates in this complex patient population. What makes tachycardia-bradycardia (tach-brady) syndrome a unique challenge in arrhythmia management? Patients who present with both AF and bradycardia, especially with syncope, require a thoughtful diagnostic approach to identify the underlying rhythm disturbance. Extended cardiac monitoring, including event monitors or implantable loop recorders, can help capture intermittent arrhythmias and correlate them with symptoms. AF may lead to atrial myopathy, and since the sinus node resides within the atrium, this can result in sinus node dysfunction—a hallmark of tachy-brady syndrome. Following spontaneous conversion from AF to sinus rhythm, sinus node dysfunction may persist, leading to prolonged pauses or chronotropic incompetence. Management becomes more complex when beta-blockers are needed for AF with RVR, as they can exacerbate bradycardia. Permanent pacemaker implantation is often the next step to consider. Permanent pacemaker implantation is often considered to facilitate safe rate control in these cases. In younger patients, aggressive AF burden reduction may prevent atrial remodeling and the development of true atrial myopathy, potentially avoiding pacemaker implantation. References Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2023;149(1). doi:https://doi.org/10.1161/CIR.0000000000001193 ‌ Van IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2024;45(36). doi:https://doi.org/10.1093/eurheartj/ehae176 ‌ Joglar JA, Kapa S, Saarel EV, et al. 2023 HRS expert consensus statement on the management of arrhythmias during pregnancy. Heart Rhythm. Published online May 1, 2023. doi:https://doi.org/10.1016/j.hrthm.2023.05.017 ‌ Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary. Journal of the American College of Cardiology. 2019;73(12):1494-1563. doi:https://doi.org/10.1016/j.jacc.2018.08.1028 ‌

With Jolanda Sabatino, Magna Graecia University of Catanzaro, Catanzaro - Italy, Salvatore De Rosa, Magna Graecia University of Catanzaro, Catanzaro - Italy and Daniele Torella, Magna Graecia University of Catanzaro, Catanzaro - Italy Link to European Heart Journal paper Link to European Heart Journal editorial

[AI UNRAVELED SPECIAL] The Biological Upgrade: Why "Surge" Exercise Protects Your Brain and Body (April 03rd 2026)

Benvenuto/a in questa puntata di BodyMind Training Podcast!Oggi parliamo di longevità e anti-aging: come vivere più a lungo e in salute, sfruttando le ultime evidenze scientifiche su stile di vita, attività fisica e gestione dello stress.

With Elena Raffetti, Karolinska Institute, Stockholm - Sweden and Mayank Dalakoti, University of Cambridge, Cambridge - UK. Link to European Heart Journal paper Link to European Heart Journal editorial

With Morton Kern, VA Long Beach and University of California, Irvine, California - USA and Arnold Seto, VA Long Beach and University of California, Irvine, California - USA. Link to European Heart Journal paper Link to European Heart Journal editorial

With Florian Kahles, RWTH University Hospital Aachen, Aachen - Germany and Berkan Kurt, RWTH University Hospital Aachen, Aachen - Germany. Link to European Heart Journal paper Link to European Heart Journal editorial

Die akute Herzinsuffizienz ist häufig die gemeinsame Endstrecke ganz unterschiedlicher Erkrankungen. Umso wichtiger ist es, die zugrunde liegenden Ursachen zu erkennen und die Zeichen einer kardialen Dekompensation richtig zu deuten.In dieser Folge von Rettungsdienst LUKS – der Notfallmedizin Podcast widmen wir uns der Pathophysiologie der akuten Herzinsuffizienz. Anhand des Akronyms CHAMPIT strukturieren wir die häufigsten Ursachen einer akuten Dekompensation und unterscheiden vier klinische Phänotypen – warm, kalt, feucht und trocken – als Grundlage für die initiale Therapiestrategie in der Präklinik.Rettungsdienst LUKS – Der Notfallmedizin Podcast mit dem Thema: Wenig vorwärts, viel rückwärts - Herzinsuffizienz systematisch erklärtIn dieser Folge: - Pathophysiologie der Herzinsuffizienz. Symptomatik des Vorwärts- und des Rückwärtsversagens- Ursachenforschung zur akuten Herzinsuffizenz mit dem Akronym CHAMPIT- Warm, kalt, feucht oder trocken? Anhand der vier Phänotypen die Herzinsuffizenz richtig TherapierenHomepage des Rettungsdienst LUKSLink zur letzten Folge zum Thema: Adieu „Grand mal“ – Neuroanatomie, Klinik und Semiologie epileptischer Anfälle  (und zu allen anderen Folgen)Alle Evidenzen zu dieser Folge findest du hier: Schmitt, D., & Güder, G. (2021). Die akute Herzinsuffizienz: Weit mehr als nur ein kardiales Problem. Notfallmedizin up2date, 16(03), 299–321. https://doi.org/10.1055/a-1341-6616Silvers, S. M., Gemme, S. R., Hickey, S., et al. (2022). Clinical Policy: Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Acute Heart Failure Syndromes. Annals of Emergency Medicine, 80(4), e31–e59. https://doi.org/10.1016/j.annemergmed.2022.05.027Heidenreich, P. A., Bozkurt, B., Aguilar, D., et al. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 79(17), e263–e421. https://doi.org/10.1016/j.jacc.2021.12.012Theresa A McDonagh, Marco Metra, Marianna Adamo, Roy S Gardner et al., 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 44, Issue 37, 1 October 2023, Pages 3627–3639, https://doi.org/10.1093/eurheartj/ehad195Tharmaratnam, G., Wunderl, M., Schebler, K., Jacko, T., Hossfeld, B., & Gässler, H. (2020). Die vier Schockformen – Teil 2: Kardiogener Schock. Der Notarzt, 36(01), 46–53. https://doi.org/10.1055/a-0991-5525Van Der Meer, P., Gaggin, H. K., & Dec, G. W. (2019). ACC/AHA Versus ESC Guidelines on Heart Failure. Journal of the American College of Cardiology, 73(21), 2756–2768. https://doi.org/10.1016/j.jacc.2019.03.478Bundesärztekammer, Kassenärztliche Bundesvereinigung und Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz – Langfassung, 2019; 3. Auflage. doi:10.6101/AZQ/000465. Im Internet (Stand: 22.07.2021): https://www.leitlinien.de/themen/herzinsuffizienzDisclaimerDie Inhalte des Podcast Rettungsdienst LUKS - Der notfallmedizin Podcast sind rein akademisch. Sie dienen nur Informations-, Lern- und Trainingszwecken und sind für ärztliches Personal, Rettungssanitäter:innen und andere im Gesundheitswesen und der Akutmedizin Tätige bestimmt. Die Inhalte sind nicht zur Behandlung realer Fälle geeignet und ersetzen keinen Arztbesuch. Der Podcast wird mit größtmöglicher Sorgfalt erstellt. Das Luzerner Kantonsspital übernimmt jedoch keine Gewähr für die Richtigkeit, Vollständigkeit und Aktualität der Inhalte.

Prepare-se para a prova de título em endocrinologia com o nosso curso: endoteem.com.br. Obtenha 40% de desconto com o cupom ENDOTEEM40.---Neste episódio discutimos as principais evidências sobre uso de análogos do GLP-1 e tirzepatida em pacientes também portadores de insuficiência cardíaca, suas limitações e cuidados na prescrição. Referências utilizadas:JORSAL, A. et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) – a multicentre, double-blind, randomised, placebo-controlled trial. European Journal of Heart Failure, Oxford, v.19, n.1, p.69–77, 2017. DOI: 10.1002/ejhf.657.KOSIBOROD, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. New England Journal of Medicine, Boston, v.389, n.12, p.1069–1084, 2023. DOI: 10.1056/NEJMoa2306963.KOSIBOROD, M. N. et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. New England Journal of Medicine, Boston, v.390, n.16, p.1394–1407, 2024. DOI: 10.1056/NEJMoa2313917.MARGULIES, K. B. et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial (FIGHT). JAMA, Chicago, v.316, n.5, p.500–508, 2016. DOI: 10.1001/jama.2016.10260.MARX, N. et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: developed by the Task Force of the European Society of Cardiology in collaboration with the EASD. European Heart Journal, Oxford, v.44, n.39, p.4043–4140, 2023. DOI: 10.1093/eurheartj/ehad192.PACKER, M. et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. New England Journal of Medicine, Boston, v.392, n.5, p.427–437, 2025. DOI: 10.1056/NEJMoa2410027.

AI Detection of Cardiac Amyloidosis   Guest: Patricia Pellikka, M.D. Host: Malcolm Bell, M.D.   Dr. Patricia Pellikka dives into the AI model she helped build. Working with an AI echo company, Ultromics Ltd., her team built an AI echo model to detect cardiac amyloidosis. The model works from an apical 4 chamber videoclip and was approved by the FDA via the breakthrough pathway. They have validated it internationally in a population with 22% prevalence of cardiac amyloidosis and it had a sensitivity of 85%, specificity 93%, PPV 78%, NPV 96%, and AUC 0.93.  The performance of the model was consistent across cardiac amyloid types; among AL, wild type ATTR, and hereditary ATTR, the sensitivity was 84%, 85%, and 86%, respectively.  The performance of the model was also superior to previously validated scores which use clinical and echocardiographic variables for detecting cardiac amyloidosis. The results of the study were published online in the European Heart Journal in July.   Topics Discussed: You have built an AI echo model to detect cardiac amyloidosis.  How did you get into this? Tell us about the model that you built. How did you validate it? How does the model compare with other screening methods for detecting cardiac amyloidosis? What are the next steps for your research?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode.   Podcast episode transcript found here.

With Pranav Mankad and Kenneth Ellenbogen, Virginia Commonwealth University Medical Center, Richmond - USA. Link to European Heart Journal paper Link to European Heart Journal editorial

Die Themen in den Wissensnachrichten: +++ Nikotin schadet auch, wenn es gelutscht oder gedampft wird +++ Pumas fressen auf einmal Pinguine in Patagonien +++ Wie man am besten Lachen unterdrücken kann +++ **********Zusätzliche InformationenNicotine and the cardiovascular system: unmasking a global public health threat, European Heart Journal, 18.12.2025A marine subsidy reshapes the ecology of a large terrestrial carnivore, Proceedings of the Royal Society B, 17.12.2025Laughter regulation in solitary and social contexts varies across emotion regulation strategies, Communications Psychology, 28.11.2025Zehn Jahre in Deutschland. Spracherwerb und Sprachförderung der Geflüchteten von 2015 und 2016, BAMF-Kurzanalyse 06/2025, 18.12.2025Children and adults across 15 countries believe in human uniqueness of mind: a cross-cultural investigation of cross-species mind perception, Journal of Environmental Psychology, Februar 2026Endophyten der Fichte: Rolle in der Abwehr von Rostpilzen, Forschungsprojekt**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

With Joao Felipe Fernandes, King's College London, London - UK and Debbie Zhao, The University of Auckland, Auckland - New Zealand. Link to European Heart Journal paper Link to European Heart Journal editorial

With Edoardo Conte, Galeazzi Sant'Ambrogio Hospital IRCCS, Milano - Italy, Daniele Andreini, Galeazzi Sant'Ambrogio Hospital IRCCS, Milan - Italy and Davide Marchetti, Galeazzi Sant'Ambrogio Hospital IRCCS, Milano - Italy. Link to European Heart Journal paper Link to European Heart Journal editorial

With Marie-Noelle Giraud, Faculty of Science and Medicine, Fribourg - Switzerland and Carolina Balbi, Research Centre for Molecular Biology, University of Zurich - Switzerland. Link to European Heart Journal paper Link to European Heart Journal editorial

With Marie-Annick Clavel, University Institute of Cardiology and Respirology of Quebec (IUCPQ), Laval University, Quebec - Canada and Paolo Springhetti, Istituto Auxologico Italiano (IRCCS), Milan - Italy. Link to European Heart Journal paper Link to European Heart Journal editorial

https://www.tadeclinicagem.com.br/guia/?utm_source=whatsapp&utm_medium=social&utm_term=&utm_content=&utm_campaign=Guia-blackfriday&utm_source_platform=&utm_creative_format=&utm_marketing_tactic=

With Domenico Filomena, Polyclinic Umberto I, Rome - Italy and Luciano Agati Sapienza, University of Rome, Rome - Italy. Link to European Heart Journal paper Link to European Heart Journal editorial

With Jonathan Lessick, Rambam Health Care Campus, Haifa - Israel and Mahmoud Suleiman, Rambam Health Care Campus, Haifa - Israel. Link to European Heart Journal paper Link to European Heart Journal editorial

With Sotiria Liori, Attikon University Hospital, National and Kapodistrian University of Athens - Greece and Julie De Backer, Ghent University Hospital - Belgium. In this episode, Sotiria Liori and Julie De Backer discuss heart failure in adult congenital heart disease patients — covering how congenital lesions and prior repairs shape epidemiology and mechanisms (ventricular remodeling, valvular and conduit dysfunction, arrhythmias), as well as clinical assessment with imaging, biomarkers, and hemodynamics. They outline management with guideline-directed therapy, rhythm considerations, indications for advanced therapies (MCS and transplant), and pregnancy counseling. The episode also highlights multidisciplinary care models and key evidence gaps. Proposed reading:  General Principles of Heart Failure Management in Adult Congenital Heart Disease. Tompkins R, Romfh A. Heart Failure Reviews. 2020;25(4):555-567. doi:10.1007/s10741-019-09895-x Chronic Heart Failure in Congenital Heart Disease: A Scientific Statement From the American Heart Association. Stout KK, Broberg CS, Book WM, et al. Circulation. 2016;133(8):770-801. doi:10.1161/CIR.0000000000000352. Relation Between New York Heart Association Functional Class and Objective Measures of Cardiopulmonary Exercise in Adults With Congenital Heart Disease. Das BB, Young ML, Niu J, et al. The American Journal of Cardiology. 2019;123(11):1868-1873. doi:10.1016/j.amjcard.2019.02.053.  Heart Failure and Patient-Reported Outcomes in Adults With Congenital Heart Disease from 15 Countries. Lu CW, Wang JK, Yang HL, Kovacs AH, et al; APPROACH‐IS consortium, the International Society for Adult Congenital Heart Disease (ISACHD) *.J Am Heart Assoc. 2022 May 3;11(9):e024993. doi: 10.1161/JAHA.121.024993. Epub 2022 Apr 26. Pharmacological Therapy in Adult Congenital Heart Disease: Growing Need, Yet Limited Evidence. Brida M, Diller GP, Nashat H, et al. European Heart Journal. 2019;40(13):1049-1056. doi:10.1093/eurheartj/ehy480. Advanced Heart Failure Therapies For Adults With Congenital Heart Disease: JACC State-of-the-Art Review. Givertz MM, DeFilippis EM, Landzberg MJ, et al. Journal of the American College of Cardiology. 2019;74(18):2295-2312.doi:10.1016/j.jacc.2019.09.004. A Review of Heart Transplantation for Adults With Congenital Heart Disease. McMahon A, McNamara J, Griffin M. Journal of Cardiothoracic and Vascular Anesthesia. 2021;35(3):752-762. doi:10.1053/j.jvca.2020.07.027. Heart Failure in Adult Congenital Heart Disease: From Advanced Therapies to End-of-Life Care. Crossland DS, Van De Bruaene A, Silversides CK, Hickey EJ, Roche SL. The Canadian Journal of Cardiology. 2019;35(12):1723-1739. doi:10.1016/j.cjca.2019.07.626. This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor. 

Beyond visible weight gain, hidden fat can build up in organs and muscles, quietly influencing long-term health A recent study published in the European Heart Journal found that where fat collects in your body is closely tied to how quickly your cardiovascular system ages The study showed that visceral fat, liver fat, and fat infiltrating muscles were strongly linked with premature cardiovascular aging Researchers also uncovered gender-specific patterns. Men tended to accumulate more visceral and abdominal fat, while women carried more subcutaneous and thigh fat To protect your heart, shift from focusing only on weight loss to improving metabolic health. Check your metabolic markers, eat the right carbs, cut seed oils, and build strength through daily movement

Did you know that congenital heart defects (CHDs) affect nearly 40,000 babies born in the United States every year? On this episode, Pediatric Cardiologist Dr. Melissa Lefebvre and medical student Marina Hashim discuss the evaluation and management of common acyanotic congenital heart conditions. Specifically, they will: Review the classification of CHDs as cyanotic versus acyanotic. Discuss the pathophysiology of the three most common acyanotic CHDs – ASD, PDA, and VSD. Describe early clinical findings and use of diagnostic tools. Cover management options, ranging from spontaneous closure to surgical intervention. Explore prognosis and long-term outcomes on physical activity, neurodevelopment, and overall health. Special thanks to Dr. Rebecca Yang and Dr. Abeer Hamdy for peer reviewing this episode. CME available free with sign up: Link Coming Soon! References: Dimopoulos, K., Constantine, A., Clift, P., & Condliffe, R. (2023). Cardiovascular complications of down syndrome: Scoping review and expert consensus. Circulation, 147(5). https://doi.org/10.1161/CIRCULATIONAHA.122.059706   Dugdale, D. C. (Ed.). (n.d.). Pediatric heart surgery - discharge. Mount Sinai. Retrieved April 26, 2024, from https://www.mountsinai.org/health-library/discharge-instructions/pediatric-heart-surgery-discharge   Eckerström, F., Nyboe, C., Maagaard, M., Redington, A., & Hjortdal, V. (2023). Survival of patients with congenital ventricular septal defect. European Heart Journal,  44 (1,1), 54-61. https://doi.org/10.1093/eurheartj/ehac618   Heart MRI. (2022, July 24). Cleveland Clinic. Retrieved April 19, 2024, from https://my.clevelandclinic.org/health/diagnostics/21961-heart-mri Leihao, S., Yajiao, L., Yunwu, Z., Yusha, T., Yucheng, C., & Lei, C. (2023). Heart-brain axis: Association of congenital heart abnormality and brain diseases. Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1071820 Meyer, K. (Ed.). (2022, May 1). What is a ventricular septal defect (VSD)? Cincinnati Children's. Retrieved March 12, 2024, from https://www.cincinnatichildrens.org/health/v/vsd Minette, M. S., & Sahn, D. S. (2006). Ventricular septal defects. Circulation, 114(20). https://doi.org/10.1161/CIRCULATIONAHA.106.618124 Mussatto, K. A., Hoffmann, R. G., Hoffman, G. M., Tweddell, J. S., Bear, L., Cao, Y., & Brosig, C. (2014). Risk and prevalence of developmental delay in young children with congenital heart disease. Pediatrics, 133(3), e570–e577. https://doi.org/10.1542/peds.2013-2309 Pruthi, S. (Ed.). (2022, October 21). Ventricular septal defect (VSD). Mayo Clinic. Retrieved April 9, 2024, from https://www.mayoclinic.org/diseases-conditions/ventricular-septal-defect/symptoms-causes/syc-20353495     Right heart catheterization. (2022, July 24). Cleveland Clinic. Retrieved April 19, 2024, from https://my.clevelandclinic.org/health/diagnostics/21045-right-heart-catheterization Shah, S., Mohanty, S., Karande, T., Maheshwari, S., Kulkarni, S., & Saxena, A. (2022). Guidelines for physical activity in children with heart disease. Annals of pediatric cardiology, 15(5-6), 467–488. https://doi.org/10.4103/apc.apc_73_22 Sigmon, E., Kellman, M., Susi, A., Nylund, C., & Oster, M. (2019). Congenital heart disease and Autism: A case-control study. Pediatrics, 144(5). https://doi.org/10.1542/peds.2018-4114 Thacker, D. (Ed.). (2022, January 1). Ventricular septal defect (VSD). Nemours Kids Health. Retrieved April 10, 2024, from https://kidshealth.org/en/parents/vsd.html   Tierney, S., & Seda, E. (2020). The benefit of exercise in children with congenital heart disease. Current Opinion in Pediatrics, 32(5), 626-632. https://doi.org/10.1097/MOP.0000000000000942  Ventricular septal defects (VSD). (2021, November 9). Cleveland Clinic. Retrieved April 2, 2024,from https://my.clevelandclinic.org/health/diseases/17615-ventricular-septal-defects-vsd    Ventricular septal defect surgery for children. (n.d.). Johns Hopkins Medicine. Retrieved April 11,2024, from https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/ventricular-septal-defect-surgery-for-children#:~:text=During%20this%20surgery%2C%20a%20surgeon,the%20hole%20between%20the%20ventricles Wernovsky, G., & Licht, D. J. (2016). Neurodevelopmental Outcomes in children with congenital heart disease - what can we impact?. Pediatric Critical Care Medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 17(8 Suppl 1), S232–S242. https://doi.org/10.1097/PCC.0000000000000800

With Maura Marcucci, Clinical Institute Humanitas IRCCS, Rozzano - Italy and McMaster University, Hamilton - Canada and Mauro Chiarito, Clinical Institute Humanitas IRCCS, Rozzano - Italy and Icahn School of Medicine at Mount Sinai, NYC - USA. Link to European Heart Journal paper Link to European Heart Journal editorial

With Jean-Benoit Le Polain de Waroux, St-Jan Hospital, Brugge - Belgium, and Maarten De Smet, AZ Sint Jan, Brugge - Belgium.  Link to European Heart Journal paper Link to European Heart Journal editorial

Nutritionist Leyla Muedin discusses the critical health impacts of visceral fat, which is the hidden fat around the organs, and its role in accelerating heart aging. Drawing from recent research conducted by the Medical Research Council and published in the European Heart Journal, she explains how visceral fat differs from subcutaneous fat and its association with inflammation, heart diseases, and premature aging. The episode also highlights the importance of exercise, diet, particularly low-carb intake, and hormone replacement therapy in managing visceral fat and reducing health risks. Leyla also shares practical dietary advice and underscores the significance of focusing on fat distribution over total body weight for better health outcomes.

With David Erlinge and Sasha Koul, Lund University, Lund - Sweden Read the European Heart Journal paper Read the European Heart Journal editorial

Vidcast:  https://www.instagram.com/p/DN038nZ3AWE/Even a mild case of CoVid will age your vital arteries 5 years.  This from a study by French cardiologists recently published in the European Heart Journal. The cardiovascular researchers studied data from 2090 individuals in 16 countries from late 2020 through early 2022.  Arterial aging was estimated by measuring the degree of vessel stiffness using pulse wave propagation measurements.  The negative effects of a CoVid infection were more significant in women and in those reporting lingering, long CoVid symptoms.On the positive side, those vaccinated against CoVid suffered less arterial stiffening following a CoVid infection.  Add this to the other benefits of vaccination including a less severe infection with a significantly lower risk of death.It's important to note that vascular aging, when “natural” or prodded along by CoVid, can be reduced by exercise, blood pressure control, healthy eating, and cholesterol-lowering medications.  Just to repeat, If unchecked, this blood vessel aging will increase your risks of a heart attack and stroke.https://medicalxpress.com/news/2025-08-covid-infection-ages-blood-vessels.htmlhttps://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf430/8236450?login=false#CoVid #coronary #vessel #stiffening #heartattack #stroke

Boire du café pour vivre plus longtemps? C'est ce que suggère une étude scientifique menée par l'université américaine de Tulane et publié début janvier dans la revue European Heart Journal. On en parle avec Thierry Favrod-Coune, médecin et addictologue aux HUG. Avec le témoignage d'Anna Possi, la barista la plus âgée d'Italie! Journaliste: Juliane Roncoroni Réalisateur: Mathieu Ballmer >> Pour aller plus loin: - "Boire du café le matin serait bénéfique pour prévenir les maladies cardiovasculaires, selon une étude", RTSinfo, 13 février 2025 (en ligne) Nous écrire ou nous proposer des questions: +41 79 134 34 70 ou pointj@rts.ch

Send us a textIn this episode of CLOT Conversations, experts discuss recent research on cancer-associated thrombosis and the predictors of recurrent venous thromboembolism (VTE) and anticoagulant-related bleeding. Dr. Faizan Khan, a leading researcher in the field, explains the results of their study that aimed to offer a comprehensive understanding of the prognostic factors associated with these risks. Hear what he says about the evidence for associations of several patient- and cancer-related factors, and the risk of recurrent VTE. This research is expected to inform clinical practice by promoting a more individualized approach to anticoagulant management in cancer patients.Reference: Khan, F., Tritschler, T., Marx, C. E., Lanting, V., Rochwerg, B., Tran, A., ... & Carrier, M. (2025). Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis. European Heart Journal, ehaf453.https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf453/8170116?login=falseSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

☕

You are called to assess a pregnant woman who presents to your hospital complaining of shortness of breath. She is 36 weeks pregnant with twins and tells you she had been getting progressively short of breath over the last month but put it down to the physical effects of the twin pregnancy in her abdomen. However last night she couldn't get her breath lying flat, had to sleep sitting up on 3-4 pillows and feels that "it is much worse". On examination she has a respiratory rate of 24/min, SpO2 = 92%, HR 105/min, BP 95/45 and you can hear crepitations in both lung fields. Her initial blood tests come back showing a raised plasma BNP and a bedside ECHO is done by a helpful colleague - who says "subjectively her LV isn't contracting very well". Hi everyone, This week I sit down with Dr Faith Njue the most qualified person here in WA to discuss the rare but important disease - peripartum cardiomyopathy. (See Faith's Bio below). Join us in our wide ranging discussion which touches on the diagnostic challenges, demographics, proposed mechanisms and general principles involved in managing these complex patients. Thanks Faith for a great discussion! Dr Faith Njue - Bio Faith Njue graduated from the University of Western Australia and completed cardiology training in Perth. She undertook further subspeciality training in advanced heart failure/ heart transplantation at Fiona Stanley Hospital and the University of Ottawa Heart Institute in Canada. Thereafter, she undertook further fellowship in cardio-obstetrics at the John Radcliffe hospital in Oxford (UK). She has special interest in women's cardiovascular health, heart disease in pregnancy and heart failure. Faith runs the dedicated Western Cardiology cardio-obstetrics clinic, designed to support women at risk of or with pre-existing heart conditions, through preconception counselling, pregnancy and into the post-partum period. Cardio-obstetrics is an expanding subspecialty that focuses on prevention, early detection, and appropriate management of cardiovascular disease in pregnancy. She holds public consultant positions at Sir Charles Gairdner and Fiona Stanley hospitals. She is part of the Advanced heart Failure and Cardiac Transplant team at FSH. She is the cardiology clinical lead for High Risk pregnancy at FSH. References Anaesthesia and peripartum cardiomyopathy Chapman, K. Njue F, Rucklidge M. BJA Education, Volume 23, Issue 12, 464 - 472 Melanie Ricke-Hoch, Tobias J. Pfeffer, and Denise Hilfiker-Kleiner. Peripartumcardiomyopathy: basic mechanisms and hope for new therapies. Cardiovascular Research (2020) 116, 520–531. doi:10.1093/cvr/cvz252​ Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2019 Jul;21(7):827-843. doi: 10.1002/ejhf.1493. Epub 2019 Jun 27. PMID: 31243866​ 2018 ESC Guidelines for the Management of Cardiovascular Disease During Pregnancy. European Heart Journal 2018. Vol 39;3165-3241​ Bromocriptine: Koenig T, Bauersachs J, Hilfiker-Kleiner D. Bromocriptine for the Treatment of Peripartum Cardiomyopathy. Card Fail Rev. 2018 May;4(1):46-49. doi: 10.15420/cfr.2018:2:2. PMID: 29892477; PMCID: PMC5971672 Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A, Schwarzkopf M, Ehlermann P, Pfister R, Michels G, Westenfeld R, Stangl V, Kindermann I, Kühl U, Angermann CE, Schlitt A, Fischer D, Podewski E, Böhm M, Sliwa K, Bauersachs J. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017 Sep 14;38(35):2671-2679. doi: 10.1093/eurheartj/ehx355. PMID: 28934837; PMCID: PMC5837241.

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-426 Overview: Drinking coffee offers potential health benefits—but does timing affect outcomes? This episode dives into new research on how morning vs. all-day coffee consumption impacts cardiovascular disease and all-cause mortality risk. Gain practical insights to optimize patient recommendations based on the latest evidence. Episode resource links: European Heart Journal (2025) 00, 1–11 https://doi.org/10.1093/eurheartj/ehae871 The Journal of Clinical Endocrinology & Metabolism, 2024, 00, 1–11 https://doi.org/10.1210/clinem/dgae552 Guest: Jillian Joseph, MPAS, PA-C   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-426 Overview: Drinking coffee offers potential health benefits—but does timing affect outcomes? This episode dives into new research on how morning vs. all-day coffee consumption impacts cardiovascular disease and all-cause mortality risk. Gain practical insights to optimize patient recommendations based on the latest evidence. Episode resource links: European Heart Journal (2025) 00, 1–11 https://doi.org/10.1093/eurheartj/ehae871 The Journal of Clinical Endocrinology & Metabolism, 2024, 00, 1–11 https://doi.org/10.1210/clinem/dgae552 Guest: Jillian Joseph, MPAS, PA-C   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-422 Overview: Conflicting data on alcohol's health effects leave clinicians uncertain about patient guidance. In this episode, we review the PREDIMED trial's findings on wine and cardiovascular outcomes, explore objective biomarkers for intake, and examine the National Academy of Sciences' recent report to clarify the risks and benefits of moderate consumption, giving you confidence in counseling patients. Episode resource links: Inés Domínguez-López, Rosa M Lamuela-Raventós, Cristina Razquin, et al. Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial, European Heart Journal, 2024;, ehae804, https://doi.org/10.1093/eurheartj/ehae804     National Academies of Sciences, Engineering, and Medicine. 2025. Review of Evidence on Alcohol and Health. Washington, DC: The National Academies Press. https://doi.org/10.17226/28582   Guest: Robert A. Baldor MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-422 Overview: Conflicting data on alcohol's health effects leave clinicians uncertain about patient guidance. In this episode, we review the PREDIMED trial's findings on wine and cardiovascular outcomes, explore objective biomarkers for intake, and examine the National Academy of Sciences' recent report to clarify the risks and benefits of moderate consumption, giving you confidence in counseling patients. Episode resource links: Inés Domínguez-López, Rosa M Lamuela-Raventós, Cristina Razquin, et al. Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial, European Heart Journal, 2024;, ehae804, https://doi.org/10.1093/eurheartj/ehae804   National Academies of Sciences, Engineering, and Medicine. 2025. Review of Evidence on Alcohol and Health. Washington, DC: The National Academies Press. https://doi.org/10.17226/28582   Guest: Robert A. Baldor MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

SpaceTime Series 28 Episode 06Formation of Pluto-Charon Binary SystemA new study reveals that the formation of the Pluto-Charon dwarf planet binary system may mirror that of the Earth-Moon system. The research, published in Nature Geoscience, suggests that both systems feature a secondary body significantly large in comparison to the primary, unlike other moons in our solar system. The findings could explain Pluto's active geology and potential subsurface ocean, highlighting the significance of giant impacts in shaping planetary bodies.BepiColombo's Final Mercury FlybyThe BepiColombo spacecraft has completed its final close flyby of Mercury, passing just 295 kilometres above the planet's surface. This manoeuvre marks the last gravity assist required for the joint ESA and JAXA mission before it enters Mercury's orbit in late 2026. The mission aims to study Mercury's magnetic field, surface composition, and interaction with the solar wind, enhancing our understanding of planets close to their host stars.Astronomy Highlights for 20252025 promises exciting astronomical events, with the Sun's solar cycle nearing its peak. Highlights include a rare edge-on view of Saturn's rings, potential brightening of comet G3 Atlas, and two lunar eclipses. The year also features significant planetary alignments, meteor showers, and opportunities to observe the Southern Cross and the centre of the Milky Way. Dr. Nick Glom provides insights into these celestial events and more.00:00 This is space Time Series 28, Episode 6 for broadcast on 13 January 202500:27 A new study suggests the formation of the Pluto Charon dwarf planet binary system04:35 BepiColombo spacecraft makes its final flyby of Mercury09:27 This is space time. We take a look at the year ahead in astronomy10:47 Mid January will be a very interesting time to look at the night sky13:05 There are two big highlights in March with the eclipse of the moon and Saturn13:46 The other big event of course is the crossing of the rings of Saturn17:03 The Southern Cross is well positioned during the month of June18:38 Venus and Jupiter are the two brightest planets in the night sky19:16 Also in August, it's a great time to have a look at Sagittarius20:35 Total eclipse of the Moon occurs when Moon moves into Earth's shadow23:06 The Australasian Sky Guide has just released its 30th edition25:05 World Meteorological Organisation confirms that 2024 was the warmest year on record29:34 It's claimed that two allegedly Celtic heads could turn you into a werewolfwww.spacetimewithstuartgary.comwww.bitesz.com

We know the literature on mechanical CPR devices on mortality in out of hospital cardiac arrest (we DO know this literature, right?), but what about in-hospital arrest? Dr. Jarvis reviews a recent paper that uses the AHA Get With The Guidelines - Resuscitation registry to assess the association between MCDs and mortality. Citations1. Crowley C, Salciccioli J, Wang W, Tamura T, Kim EY, Moskowitz A: The association between mechanical CPR and outcomes from in-hospital cardiac arrest: An observational cohort study. Resuscitation. 2024;May 1;198.2. Rubertsson S, Lindgren E, Smekal D, Östlund O, Silfverstolpe J, Lichtveld RA, Boomars R, Ahlstedt B, Skoog G, Kastberg R, et al.: Mechanical Chest Compressions and Simultaneous Defibrillation vs Conventional Cardiopulmonary Resuscitation in Out-of-Hospital Cardiac Arrest: The LINC Randomized Trial. JAMA. 2014;January 1;311(1):53–613. Hardig BM, Lindgren E, Östlund O, Herlitz J, Karlsten R, Rubertsson S: Outcome among VF/VT patients in the LINC (LUCAS IN cardiac arrest) trial—A randomised, controlled trial. Resuscitation. 2017;June;115:155–62.4.  Perkins GD, Lall R, Quinn T, Deakin CD, Cooke MW, Horton J, Lamb SE, Slowther A-M, Woollard M, Carson A, et al.: Mechanical versus manual chest compression for out-of-hospital cardiac arrest (PARAMEDIC): a pragmatic, cluster randomised controlled trial. The Lancet. 2015;385(9972):947–55.5.  Wik L, Olsen J-A, Persse D, Sterz F, Lozano M, Brouwer MA, Westfall M, Souders CM, Malzer R, Van Grunsven PM, et al.: Manual vs. integrated automatic load-distributing band CPR with equal survival after out of hospital cardiac arrest. The randomized CIRC trial. Resuscitation. 2014;June;85(6):741–8.6. Bonnes JL, Brouwer MA, Navarese EP, Verhaert DVM, Verheugt FWA, Smeets JLRM, Boer M-J de: Manual Cardiopulmonary Resuscitation Versus CPR Including a Mechanical Chest Compression Device in Out-of-Hospital Cardiac Arrest: A Comprehensive Meta-analysis From Randomized and Observational Studies. Ann Emerg Med Annals of emergency medicine. 2016;67(3):349-360.e3.7. Gonzales L, Oyler BK, Hayes JL, Escott ME, Cabanas JG, Hinchey PR, Brown LH: Out-of-hospital cardiac arrest outcomes with “pit crew” resuscitation and scripted initiation of mechanical CPR. The American Journal of Emergency Medicine. 2019;May;37(5):913–20.8. Koster RW, Beenen LF, Van Der Boom EB, Spijkerboer AM, Tepaske R, Van Der Wal AC, Beesems SG, Tijssen JG: Safety of mechanical chest compression devices AutoPulse and LUCAS in cardiac arrest: a randomized clinical trial for non-inferiority. European Heart Journal. 2017;October 21;38(40):3006–13.9. Primi R, Bendotti S, Currao A, Sechi GM, Marconi G, Pamploni G, Panni G, Sgotti D, Zorzi E, Cazzaniga M, et al.: Use of Mechanical Chest Compression for Resuscitation in Out-Of-Hospital Cardiac Arrest—Device Matters: A Propensity-Score-Based Match Analysis. JCM. 2023;June 30;12(13):4429.10. Youngquist ST, Ockerse P, Hartsell S, Stratford C, Taillac P: Mechanical chest compression devices are associated with poor neurological survival in a statewide registry: A propensity score analysis. Resuscitation. 2016;September;106:102–7.11.  S, Sulzgruber P, Datler P, Keferböck M, Poppe M, Lobmeyr E, Van Tulder R, Zajicek A, Buchinger A, Polz K, et al.: Mechanical chest compression does not seem to improve outcome after out-of hospital cardiac arrest. A single center observational trial. Resuscitation. 2015;November;96:220–5. 12. Morgan S, Gray JJ, Sams W, Uhl K, Gundrum M, McMullan J: LUCAS Device Use Associated with Prolonged Pauses during Application and Long Chest Compression Intervals. Prehospital Emergency Care. doi: 10.1080/10903127.2023.2183294 (Epub ahead of print).13.  Levy M, Yost D, Walker RG, Scheunemann E, Mendive SR: A quality improvement initiative to optimize use of a mechanical chest compression device within a high-performance CPR approach to out-of-hospital cardiac arrest resuscitation. Resuscitation. 2015;July;92:32–7.14.  Li H, Wang D, Yu Y, Zhao X, Jing X: Mechanical versus manual chest compressions for cardiac arrest: a systematic review and meta-analysis. Scand J Trauma Resusc Emerg Med. 2016;December;24(1):10.15.  Sheraton M, Columbus J, Surani S, Chopra R, Kashyap R: Effectiveness of Mechanical Chest Compression Devices over Manual Cardiopulmonary Resuscitation: A Systematic Review with Meta-analysis and Trial Sequential Analysis. WestJEM. 2021;July 19;22(4):810–9.16.  Wang PL, Brooks SC: Mechanical versus manual chest compressions for cardiac arrest. Cochrane Database Syst Rev The Cochrane database of systematic reviews. 2018;20;8:CD007260.17.  Zhu N, Chen Q, Jiang Z, Liao F, Kou B, Tang H, Zhou M: A meta-analysis of the resuscitative effects of mechanical and manual chest compression in out-of-hospital cardiac arrest patients. Crit Care. 2019;December;23(1):100.